|
KMID : 0358419940370050937
|
|
Korean Journal of Obstetrics and Gynecology
1994 Volume.37 No. 5 p.937 ~ p.945
|
|
|
The Clinical Evaluation of Cefbuperazone (tomiporan )in the Treatment of Femals Pelvic Inflammatory Disease
|
|
민혜원
김시영/이윤호/김주덕/황동훈
|
|
|
Abstract
|
|
|
This study was examined to evaluate the clinical efficacy of the cefbuperazone in 40 patients with pelvic inflammatory disease, who visited the department of obstetrics and gynecology, Yonsei university college of medicine from August 1991
through
July
1992.
The mean age of the patients was 34.0 years(range 19 to 40 years). The total isolated organisms were 47 strains. Among them the aerobes were 32 strains(68.1%) and the anaerobes were 15 strains(31.9%).
Bacteriological response of cefbuperazone was superior than that of ampicillin & cephalothin in vitro susceptabillity tests. The cefbuperazone was sensitive to all isolated organisms except enterococcus which was more sensitive to ampicillin.
Minimum inhibitory concentration (MIC) of cefbuperazone for most of the isolated organisms except enterococcus was less than 4μg/ml. The eradication rate, in the bacteriologic response of cefbuperazone, was 82.7%, and the clinical efficacy rate
of
cefbuperazone was 100%. There was no remarkable side effect.
Our results suggest that the cefbuperazone is recommended for the treatment of patients with pelvic inflammatory disease, but it will be required further clinical reports.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|